Clinical trial

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

Recruiting now · Not applicable · 1 countries · Registry ID NCT07272837

Recruiting nowNot applicableObservational

What this study is about

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss. This study involves (3) in-person study visits. At each visit, participants will be asked to: * Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected from a vein in your arm. * Have your blood levels assessed through three finger pricks. * Complete three days of food records.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 80 Years

SexAll

Healthy volunteersNot accepted

ConditionType 2 Diabetes, Obesity, Semaglutide, GLP-1, Diabetes

Full registry criteria

Inclusion Criteria: * Adults 18-80 years of age * Starting semaglutide for type 2 diabetes or weight loss * Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment) Exclusion Criteria: * Current use of semaglutide for more than 2 weeks * Major recent heart issues or other severe health conditions * Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia) * Dependence on a mobility aid (unable to participate in exercise MRI)

Treatments and study arms

The registry does not list a named intervention.

Primary outcomes

Changes in skeletal and cardiac muscle mass12 months

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Mazankowski Alberta Heart Institute🇨🇦 Edmonton, Alberta, Canada

Open map

Krista JongContact

Email · Call 780-492-9010